Changes in vancomycin pharmacokinetics during treatment

Therapeutic Drug Monitoring

Volumn 18, Issue 2, 1996, Pages 149-153

  Pou, L ^a   Rosell, M ^a   Lopez, R ^a   Pascual, C ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Pharmacokinetics; Vancomycin

Indexed keywords

CREATININE; VANCOMYCIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; STEADY STATE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; VANCOMYCIN;

EID: 0030012262     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199604000-00007     Document Type: Article

References (24)

1. Moellering RC, Krogstad DJ, Greenblatt DJ. Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med 1981;94:343-6.
2. Ena J, Dick RW, Jones RN, Wenzel RP. The epidemiology of intravenous vancomycin usage in a university hospital: a 10-year study. JAMA 1993;269:598-602.
3. Rodvold KA, Zokufa H, Rotschafer JC. Routine monitoring of serum vancomycin concentrations: can waiting be justified? [Commentary.] Clin Pharmacol 1987;6:655-8.
4. Sayers JFB, Shimasaki R. Routine monitoring of serum vancomycin concentrations: the answer lies in the middle. Clin Pharmacol 1988;7:18.
5. Garrelts JC, Godley PJ, Horton MW, Karboski JA. Accuracy of Bayesian, Sawchuk-Zaske, and nomogram dosing methods for vancomycin. Clin Pharmacol 1987;6:795-9.
6. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
7. Macias WL, Mueller BA, Scarim SK. Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance. Clin Pharmacol Ther 1991;50:688-94.
8. Cutler NR, Narang PL, Lesko LJ, Ninos M, Power M. Vancomycin disposition: the importance of age. Clin Pharmacol Ther 1984;36:803-10.
9. Vance-Bryan K, Guay DRP, Gilliland SS, Rodvold KA, Rotschafer JC. Effect of obesity on vancomycin pharmacokinetics parameters as determined by using a bayesian forecasting technique. Antimicrob Agents Chemother 1993;37: 436-40.
10. Brown J, Altmann P, Cunningham J, Shaw E, Marsch F. Pharmacokinetics of once daily intra-peritoneal aztreonam and vancomycin in the treatment of CAPD peritonitis. J Antimicrob Chemother 1990;25:141-7.
11. Tan CC, Lee HS, Ti TY, Lee EJC. Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure. Ther Drug Monit 1990;12:29-34.
12. Hoie EB, Swigart SA, Leuschen MP, et al. Vancomycin pharmacokinetics in infants undergoing extracorporal membrane oxygenation. Clin Pharmacol 1990;9:711-5.
13. Cimino MA, Rotstein C, Slaughter RL, Emrich LJ. Relationship of serum antibiotic concentration to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy. Am J Med 1987;83:1091-7.
14. Rybak MJ, Albrecht LM, Boike SC, Chandrasekar PH. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 1990;25:679-87.
15. Matzke GR. Vancomycin. In: Evans WE, Shetang JJ, Jusko WJ, eds. Applied pharmacokinetics: principles of therapeutic drug monitoring. Washington: Applied Therapeutics, Inc., 1986:399-136.
16. Albrecht LM, Rybak MJ, Boike SC, Pancorbo S. Comparison of serum sampling methods for determining vancomycin dosage regimens. Ther Drug Monit 1988;10:85-90.
17. Pryka RD, Rodvold KA, Garrison M, Rotschafer JC. Individualizing vancomycin dosage regimen: one- vs two-compartment Bayesian models. Ther Drug Monit 1989;11: 450-4.
18. Vance-Bryan K, Rotschafer JC, Gilliland SS, Rodvold KA, Fitzgerald, Guay RP. A comparative assessment of vancomycin-associated nephrotoxicity in the young versus elderly hospitalized patient. J Antimicrob Chemother 1994;33:811-21.
19. Miller JR, Garner AW. Unpredictable vancomycin excretion in an elderly patient with adequate renal function. ASHP Midyear Clinical Meeting. 1990; 25:P-181D.
20. Rotschafer JC, Crossley K, Zaske DE, Sawchuk RJ, Solem LD. Pharmacokinetics of vancomycin: observations in twenty-eight patients and dosage recommendations. Antimicrob Agents Chemother 1982;22:391-4.
21. Golper TA, Noonan HM, Elzinga L, et al. Vancomycin pharmacokinetics, renal handling, and nonrenal clearances in normal human subjects. Clin Pharmacol Ther 1988;43: 565-70.
22. Sun HE, Maderazo EG, Krusell AR. Serum protein-binding characteristics of vancomycin. Antimicrob Agents Chemother 1993;37:1132-6.
23. Brown N, Ho DHW, Fong KL, et al. Effects of hepatic function on vancomycin clinical pharmacology. Antimicrob Agents Chemother 1983;23:603-9.
24. Wood CA, Kohlhepp SJ, Kohnen PW, Houghton DC, Gilbert DN. Vancomycin enhancement of experimental tobramycin toxicity. Antimicroh Agents Chemother 1986;30: 20-4.